zuclopenthixol acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4075 | 85721-05-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blood prolactin abnormal | 961.33 | 176.65 | 156 | 2418 | 2923 | 63483525 |
| Anosognosia | 955.51 | 176.65 | 156 | 2418 | 3040 | 63483408 |
| Disturbance in social behaviour | 920.81 | 176.65 | 156 | 2418 | 3837 | 63482611 |
| Sexual dysfunction | 907.14 | 176.65 | 156 | 2418 | 4203 | 63482245 |
| Metabolic disorder | 844.82 | 176.65 | 156 | 2418 | 6347 | 63480101 |
| Personality change | 776.85 | 176.65 | 147 | 2427 | 6826 | 63479622 |
| Dystonia | 727.51 | 176.65 | 156 | 2418 | 13663 | 63472785 |
| Dyskinesia | 606.92 | 176.65 | 158 | 2416 | 31844 | 63454604 |
| Sedation | 595.45 | 176.65 | 162 | 2412 | 38647 | 63447801 |
| Suicide attempt | 502.09 | 176.65 | 157 | 2417 | 60761 | 63425687 |
| Blood glucose increased | 449.09 | 176.65 | 156 | 2418 | 83600 | 63402848 |
| Insurance issue | 194.88 | 176.65 | 46 | 2528 | 6075 | 63480373 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blood prolactin abnormal | 299.64 | 55.36 | 51 | 1877 | 918 | 34954085 |
| Anosognosia | 299.43 | 55.36 | 51 | 1877 | 922 | 34954081 |
| Disturbance in social behaviour | 260.45 | 55.36 | 50 | 1878 | 1801 | 34953202 |
| Metabolic disorder | 224.03 | 55.36 | 51 | 1877 | 4232 | 34950771 |
| Sexual dysfunction | 209.45 | 55.36 | 52 | 1876 | 6251 | 34948752 |
| Dystonia | 195.04 | 55.36 | 55 | 1873 | 10790 | 34944213 |
| Dyskinesia | 182.94 | 55.36 | 62 | 1866 | 22351 | 34932652 |
| Personality change | 163.67 | 55.36 | 41 | 1887 | 5098 | 34949905 |
| Sedation | 121.34 | 55.36 | 45 | 1883 | 20961 | 34934042 |
| Blood glucose increased | 98.12 | 55.36 | 55 | 1873 | 66663 | 34888340 |
| Suicide attempt | 91.29 | 55.36 | 44 | 1884 | 39072 | 34915931 |
| Anxiolytic therapy | 61.34 | 55.36 | 9 | 1919 | 57 | 34954946 |
| Drug therapy enhancement | 60.19 | 55.36 | 9 | 1919 | 66 | 34954937 |
| Neuroleptic malignant syndrome | 60.15 | 55.36 | 26 | 1902 | 17908 | 34937095 |
| Iatrogenic injury | 59.32 | 55.36 | 13 | 1915 | 898 | 34954105 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blood prolactin abnormal | 1064.23 | 63.80 | 180 | 3882 | 3421 | 79736905 |
| Anosognosia | 1056.26 | 63.80 | 180 | 3882 | 3584 | 79736742 |
| Disturbance in social behaviour | 1006.29 | 63.80 | 180 | 3882 | 4790 | 79735536 |
| Sexual dysfunction | 932.33 | 63.80 | 181 | 3881 | 7582 | 79732744 |
| Metabolic disorder | 896.25 | 63.80 | 180 | 3882 | 8990 | 79731336 |
| Personality change | 830.69 | 63.80 | 172 | 3890 | 9998 | 79730328 |
| Dystonia | 759.79 | 63.80 | 183 | 3879 | 21216 | 79719110 |
| Dyskinesia | 670.41 | 63.80 | 193 | 3869 | 44580 | 79695746 |
| Sedation | 620.64 | 63.80 | 188 | 3874 | 51707 | 79688619 |
| Suicide attempt | 514.88 | 63.80 | 183 | 3879 | 82749 | 79657577 |
| Blood glucose increased | 456.65 | 63.80 | 183 | 3879 | 114792 | 79625534 |
| Insurance issue | 218.10 | 63.80 | 52 | 4010 | 5681 | 79734645 |
| Adverse drug reaction | 177.20 | 63.80 | 80 | 3982 | 66312 | 79674014 |
| Drug ineffective | 118.36 | 63.80 | 202 | 3860 | 1080711 | 78659615 |
| Condition aggravated | 95.54 | 63.80 | 122 | 3940 | 501002 | 79239324 |
| Personality change due to a general medical condition | 70.60 | 63.80 | 12 | 4050 | 230 | 79740096 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.47 | Basic |
| pKa2 | 3.47 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| C0149491 | UMLSCUI |
| CHEBI:135722 | CHEBI |
| C060342 | MESH_SUPPLEMENTAL_RECORD_UI |
| 349S2ZHF05 | UNII |
| 6436640 | PUBCHEM_CID |
| DB13841 | DRUGBANK_ID |
| 58338 | RXNORM |
| 004070 | NDDF |
| 387566002 | SNOMEDCT_US |
| 395931006 | SNOMEDCT_US |
| 427940003 | SNOMEDCT_US |
| C0009026 | UMLSCUI |
| 1315 | INN_ID |
| 5311507 | PUBCHEM_CID |
| D003006 | MESH_DESCRIPTOR_UI |
Pharmaceutical products:
None